Dasatinib: in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
about
Eph receptors and ephrin ligands: important players in angiogenesis and tumor angiogenesisSystematic review of dasatinib in chronic myeloid leukemiaDasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia.Spotlight on dasatinib in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.Anomalous constitutive Src kinase activity promotes B lymphoma survival and growth.Striking the target in Wnt-y conditions: intervening in Wnt signaling during cancer progressionEph receptors and ephrins as targets for cancer therapy.Dasatinib-related chylothoraxBCR/ABL can promote CD19+ cell growth but not render them long-term stemness.Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development.Activity and safety of dasatinib as second-line treatment or in newly diagnosed chronic phase chronic myeloid leukemia patients.The current role of high-dose imatinib in chronic myeloid leukemia patients, newly diagnosed or resistant to standard dose.Genetic characterization to improve interpretation and clinical management of hepatotoxicity caused by tyrosine kinase inhibitors.Bioimaging analysis of nuclear factor-κB activity in Philadelphia chromosome-positive acute lymphoblastic leukemia cells reveals its synergistic upregulation by tumor necrosis factor-α-stimulated changes to the microenvironment.Dasatinib for a child with Philadelphia chromosome-positive acute lymphoblastic leukemia and persistently elevated minimal residual disease during imatinib therapyDevelopment of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia.Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.Dasatinib-induced acute hepatitis.Dasatinib in chronic myeloid leukemia: a limited Indian experience.
P2860
Q21328694-A13FEADB-B104-4611-B65D-D270A15787DEQ24596026-A26ACCB0-A3F6-4AA2-8CD4-AF27875817A5Q33397085-451E4BE0-ACDC-41BC-9EA3-ABB81AAA00E5Q33399101-D2DEE81F-8648-4820-8A2B-102391C8EAC2Q33623874-336DC3DE-4260-4B4D-8F84-28790EB7A4E2Q33965278-A7B61CDB-6B1E-468F-AA96-45AF7287F212Q35370195-F9643F6F-07FA-4CE9-906C-E9E45E6DEDDBQ35631562-770B81C2-1528-4F22-9D7A-FD678EB779FAQ37531026-3796753F-2DFD-4C49-9328-993F9E2EE685Q37781050-0DDD3E55-E91C-40E3-BD36-641AE7F9615DQ37870181-E260AE85-8BD2-49F8-B32C-94F6754489AEQ37896606-D6DBD543-9E95-4CCE-B2A8-77EAF96850A7Q38095989-B344EF0E-9F3D-4C19-9A96-6514033CBE59Q39503233-1D371ED4-9978-4971-A3B2-D3CA712EDD02Q41863632-73999135-E9AA-4A44-B13B-6A87454ED33FQ42017483-E4594297-6249-42F5-9D8A-48C68393CBB3Q43841175-0551BB4D-FD6F-49AB-A2FB-D7D626FA038FQ46496023-FDA0C6C5-06B8-4AD8-BAA3-33E41E332303Q54490451-B3771957-6D73-4549-A852-0D85C59C48E3
P2860
Dasatinib: in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Dasatinib: in chronic myeloid ...... acute lymphoblastic leukemia.
@en
Dasatinib: in chronic myeloid ...... acute lymphoblastic leukemia.
@nl
type
label
Dasatinib: in chronic myeloid ...... acute lymphoblastic leukemia.
@en
Dasatinib: in chronic myeloid ...... acute lymphoblastic leukemia.
@nl
prefLabel
Dasatinib: in chronic myeloid ...... acute lymphoblastic leukemia.
@en
Dasatinib: in chronic myeloid ...... acute lymphoblastic leukemia.
@nl
P1433
P1476
Dasatinib: in chronic myeloid ...... e acute lymphoblastic leukemia
@en
P2093
Susan J Keam
P356
10.2165/00063030-200822010-00007
P50
P577
2008-01-01T00:00:00Z
P5875
P6179
1038353645